UCB Presents Two-Year Data of Bimekizumab in BE BRIGHT Trial for the Treatment of Moderate to Severe Plaque Psoriasis at AAD 2021

Shots: The ongoing BE BRIGHT, OLE trial evaluates the safety, tolerability, and efficacy of bimekizumab (q4w/q8w) in 989 patients with the mod. to sev. PsO The interim data showed that @16wks., 9/10 patients achieved clear or almost clear skin (IGA 0/1), 8/10 patients achieved complete skin clearance (PASI 100) and maintained responses through 2yrs. with …

UCB Presents Two-Year Data of Bimekizumab in BE BRIGHT Trial for the Treatment of Moderate to Severe Plaque Psoriasis at AAD 2021 Read More »